<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; shareholders</title>
	<atom:link href="http://www.tapanray.in/tag/shareholders/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>Managing Pharma Investors’ Expectations When The Chips Are Down</title>
		<link>http://www.tapanray.in/managing-pharma-investors-expectations-when-the-chips-are-down/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=managing-pharma-investors-expectations-when-the-chips-are-down</link>
		<comments>http://www.tapanray.in/managing-pharma-investors-expectations-when-the-chips-are-down/#comments</comments>
		<pubDate>Sun, 18 Jun 2017 23:34:19 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[accountability.]]></category>
		<category><![CDATA[activist]]></category>
		<category><![CDATA[bans]]></category>
		<category><![CDATA[Business]]></category>
		<category><![CDATA[Chips]]></category>
		<category><![CDATA[Compliance]]></category>
		<category><![CDATA[domestic]]></category>
		<category><![CDATA[down]]></category>
		<category><![CDATA[Ethics]]></category>
		<category><![CDATA[expectations]]></category>
		<category><![CDATA[export]]></category>
		<category><![CDATA[import]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Investors]]></category>
		<category><![CDATA[Managing]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[pain]]></category>
		<category><![CDATA[Points]]></category>
		<category><![CDATA[practices]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Regulatory]]></category>
		<category><![CDATA[shareholders]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[Trump]]></category>
		<category><![CDATA[USFDA]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=8282</guid>
		<description><![CDATA[Triggered by several critical factors, over a relatively short period of time, a downward spiral is visible with most Indian Pharma stocks, with a significant erosion in market capitalization of many large players in the country. A set of important &#8230; <a href="http://www.tapanray.in/managing-pharma-investors-expectations-when-the-chips-are-down/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/managing-pharma-investors-expectations-when-the-chips-are-down/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Pharma industry requires striking a right balance between ethical obligations to shareholders and ethical obligations to patients</title>
		<link>http://www.tapanray.in/pharma-industry-requires-striking-a-right-balance-between-ethical-obligations-to-shareholders-and-ethical-obligations-to-patients/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=pharma-industry-requires-striking-a-right-balance-between-ethical-obligations-to-shareholders-and-ethical-obligations-to-patients</link>
		<comments>http://www.tapanray.in/pharma-industry-requires-striking-a-right-balance-between-ethical-obligations-to-shareholders-and-ethical-obligations-to-patients/#comments</comments>
		<pubDate>Mon, 24 Sep 2012 00:00:29 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[a]]></category>
		<category><![CDATA[abbott]]></category>
		<category><![CDATA[and]]></category>
		<category><![CDATA[balance]]></category>
		<category><![CDATA[between]]></category>
		<category><![CDATA[Biotech]]></category>
		<category><![CDATA[Clinical]]></category>
		<category><![CDATA[Compulsory Licensing]]></category>
		<category><![CDATA[Counterfeit]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[ethical]]></category>
		<category><![CDATA[Ethical Marketing]]></category>
		<category><![CDATA[FDI]]></category>
		<category><![CDATA[glaxo]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Hospital]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[IPR]]></category>
		<category><![CDATA[kopran]]></category>
		<category><![CDATA[Legal]]></category>
		<category><![CDATA[Medical Diagnostics]]></category>
		<category><![CDATA[medicine]]></category>
		<category><![CDATA[Neutraceutical]]></category>
		<category><![CDATA[NPPA]]></category>
		<category><![CDATA[obligations]]></category>
		<category><![CDATA[OPPI]]></category>
		<category><![CDATA[Patents]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[Patients]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[PHC]]></category>
		<category><![CDATA[Policy]]></category>
		<category><![CDATA[Pricing]]></category>
		<category><![CDATA[RDP]]></category>
		<category><![CDATA[Regulatory]]></category>
		<category><![CDATA[requires]]></category>
		<category><![CDATA[Research & Development]]></category>
		<category><![CDATA[right]]></category>
		<category><![CDATA[sami]]></category>
		<category><![CDATA[shareholders]]></category>
		<category><![CDATA[Spurious]]></category>
		<category><![CDATA[stakeholders]]></category>
		<category><![CDATA[strategy]]></category>
		<category><![CDATA[striking]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[therapeutic]]></category>
		<category><![CDATA[to]]></category>
		<category><![CDATA[Trials]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=6</guid>
		<description><![CDATA[On September 15, 2012, while delivering his keynote address in a pharmaceutical industry function, Dr. Sam Pitroda, the Chicago based Indian, creator of the telecom revolution in India and the Advisor to the Prime Minister on Public Information, Infrastructure &#38; &#8230; <a href="http://www.tapanray.in/pharma-industry-requires-striking-a-right-balance-between-ethical-obligations-to-shareholders-and-ethical-obligations-to-patients/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/pharma-industry-requires-striking-a-right-balance-between-ethical-obligations-to-shareholders-and-ethical-obligations-to-patients/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
